RUBRA MEDICAMENTS LTD. - 531099 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of newspaper publication of notice of Annual General Meeting Date of AGM - September 30, 202205-09-2022
05-09-2022
RUBRA MEDICAMENTS LTD. - 531099 - Reg. 34 (1) Annual Report.
Annual Report of the Company for the FY 2021-2203-09-2022
RUBRA MEDICAMENTS LTD. - 531099 - Notice Of Annual General Meeting
In compliance with Regulation 29 of the SEBI (LODR) Regulations, 2015, please find attached herewith Notice of Annual General Meeting Date of Annual General Meeting - September 30, 2022.03-09-2022
RUBRA MEDICAMENTS LTD. - 531099 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of newspaper publication of unaudited Financial Results for the quarter ended June 30, 202216-08-2022
RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting11-08-2022
RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Intimation for Notice Of Board Meeting
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2022 ,inter alia, to consider and approve 1. Standalone Unaudited Financial Results along with limited review report of the Company for the quarter ended June 30, 2022. The Company shall intimate to the exchange the unaudited Financial Results upon the conclusion of the Board Meeting as required by SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Reappointment of Ms. Sneha Thakur (DIN: 07805202) as an Independent Director for a further period of 5 years from July 7, 2022 till July 6, 2027 subject to approval of members in forthcoming Annual General Meeting 3. To fix the dates of Book Closure for Annual General Meeting. 4. To decide the time, venue and date of Annual General Meeting.01-08-2022
RUBRA MEDICAMENTS LTD. - 531099 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Abha KapoorDesignation :- Managing Director / Whole Time Director05-07-2022
RUBRA MEDICAMENTS LTD. - 531099 - Closure of Trading Window
The Trading Window for dealing in the Company''s Equity Shares will remain closed from Friday, July 1, 2022 for all Designated Employees of the Company. The closure is in connection with the declaration of financial results of the Company for the quarter ending June 30, 2022.28-06-2022
RUBRA MEDICAMENTS LTD. - 531099 - Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended March 31, 2022
Certificate under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 202202-06-2022
RUBRA MEDICAMENTS LTD. - 531099 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of newspaper publication of audited Financial Results for the quarter and year ended March 31, 202228-05-2022